Neurocrine Biosciences Inc

2026. g. 6. nov. 20:51 UTC

Neurocrine Biosciences announces survey results showing adults with tardive dyskinesia experienced fewer work and school disruptions after starting treatment with INGREZZA®.

2026. g. 5. nov. 21:04 UTC

Neurocrine Biosciences reports survey findings showing significant reductions in work and school disruptions for adults with tardive dyskinesia after starting INGREZZA treatment.

2026. g. 4. nov. 20:41 UTC

Guggenheim raises Neurocrine Biosciences price target to $224 from $207 while maintaining a Buy rating, amid positive sentiment and strong sector performance.

2026. g. 3. nov. 23:41 UTC

Neurocrine Biosciences, Inc. shares are declining in after-market trading, moving lower since Tuesday's close, shifting from a low of 1.15% to 1.00%.

2026. g. 2. nov. 23:02 UTC

Neurocrine Biosciences raises full-year 2026 INGREZZA net product sales guidance to $2.9B-$2.925B and reports Q3 revenue of $1.123B, exceeding estimates.

2026. g. 30. okt. 20:22 UTC

Neurocrine Biosciences, Inc. is declining in after-market trading, following a regular session close that was also lower.

2026. g. 29. okt. 19:46 UTC

Neurocrine Biosciences, Inc. is trading modestly higher, positioned near the upper end of its one-month range and above its 20-day moving average.

2026. g. 28. okt. 20:31 UTC

Neurocrine Biosciences, Inc. rose in after-market trading, peaking significantly above Wednesday's close and remaining well above its 20-day moving average.

2026. g. 26. okt. 20:07 UTC

Neurocrine Biosciences presents research establishing a 6-point EQ-VAS increase as the benchmark for meaningful health improvement in tardive dyskinesia patients treated with INGREZZA.

2026. g. 23. okt. 20:07 UTC

Neurocrine Biosciences Inc shares are declining amid a broader market downturn, influenced by rising oil prices and mixed economic data.

2026. g. 22. okt. 20:07 UTC

Neurocrine Biosciences Inc shares advanced, peaking in mid-afternoon and settling near daily highs, remaining well above its 20-day moving average.

2026. g. 20. okt. 20:02 UTC

Neurocrine Biosciences initiates a Phase 2 clinical study for NBI-1117567 in adults with mild to moderate Alzheimer's disease, enrolling approximately 135 participants.

2026. g. 16. okt. 19:46 UTC

Neurocrine Biosciences presents new real-world data on classic congenital adrenal hyperplasia at the Endocrine Nurses Society Annual Symposium, highlighting patient care challenges.

2026. g. 15. okt. 23:11 UTC

Neurocrine Biosciences Inc is gaining in after-market trading, continuing a trend of higher closes over the past three sessions, though still below its 20-day moving average.

2026. g. 13. okt. 20:01 UTC

Neurocrine Biosciences Inc declines as RBC maintains an Outperform rating and sets a price target of $187, following concerns over Vykat's safety linked to seven deaths.

2026. g. 12. okt. 20:13 UTC

Neurocrine Biosciences will hold a conference call and webcast on November 2, 2026, to discuss its third quarter financial results.

2026. g. 9. okt. 20:06 UTC

Neurocrine Biosciences Inc shares are modestly higher, showing a moderate upward move after earlier fluctuations, though still below its 20-day moving average.

2026. g. 8. okt. 20:01 UTC

Neurocrine Biosciences Inc shares fell sharply, remaining below their 20-day moving average and near the lower end of their one-month range.

2026. g. 6. okt. 19:45 UTC

Neurocrine Biosciences shares are higher as Guggenheim analyst Delma Caiati initiates coverage with a Buy rating and a $207 price target.

2026. g. 5. okt. 20:20 UTC

Neurocrine Biosciences Inc is trading modestly lower in after-market hours, moving deeper into decline since Monday's close and near the lower end of its one-month range.

2026. g. 2. okt. 20:07 UTC

Neurocrine Biosciences Inc is trading higher, reflecting broader market performance, though it remains below its 20-day moving average and near the lower end of its one-month range.

2026. g. 1. okt. 20:07 UTC

Neurocrine Biosciences Inc shares fell modestly, closing lower after briefly peaking, and remain significantly below their 20-day moving average.

2026. g. 30. sept. 20:07 UTC

Neurocrine Biosciences will present eight studies on VYKAT XR at the Foundation for Prader-Willi Research symposium, contributing to its stock's gains since Tuesday.

2026. g. 29. sept. 20:07 UTC

Neurocrine Biosciences shares fell after UBS maintained its Buy rating but lowered the price target to $214 amid leadership changes.

2026. g. 28. sept. 23:55 UTC

Neurocrine Biosciences shares rise in after-market trading following the return of Eiry W. Roberts, M.D., as Chief Medical Officer, ensuring continuity for late-stage programs.

2026. g. 25. sept. 20:07 UTC

Neurocrine Biosciences Inc shares fell, continuing a downward trend for six sessions, significantly below the 20-day moving average amid broader market declines.

2026. g. 24. sept. 20:07 UTC

Neurocrine Biosciences Inc shares fell, marking the sixth consecutive session of lower closes and remaining significantly below the 20-day moving average.

2026. g. 23. sept. 20:01 UTC

Neurocrine Biosciences Inc shares fell, continuing a downward trend for four sessions and trading significantly below the 20-day moving average.

2026. g. 21. sept. 20:06 UTC

Neurocrine Biosciences shares fell sharply after RBC Capital cut its price target to $187.00 from $198.00, citing concerns over near-term performance.

2026. g. 18. sept. 20:02 UTC

Neurocrine Biosciences Inc shares fell sharply, breaking a trend of higher daily closes following a decline since Thursday's close.